Inhibikase Therapeutics, Inc. (IKT) vs Century Therapeutics, Inc. (IPSC)
Inhibikase Therapeutics, Inc. and Century Therapeutics, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Century Therapeutics, Inc. are of similar size ($306.0M and $293.0M). Century Therapeutics, Inc. grew revenue faster over the last twelve months: 8,286.7% against 110.9%. Across the 12 metrics below, Century Therapeutics, Inc. leads on 7 and Inhibikase Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | IKT | IPSC | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% | 0.00% |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (51.96%) | (49.65%) | (57.72%) |
| Return on assets | (48.04%) | (38.41%) | (49.22%) |
| Return on invested capital | 0.00% | (64.92%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack